middle.news
AdAlta Advances Cellular Immunotherapy Pipeline, Secures First Asset and Raises A$5.3 Million
4:58pm on Friday 21st of August, 2026 AEST
•
Biotechnology
Read Story
AdAlta Advances Cellular Immunotherapy Pipeline, Secures First Asset and Raises A$5.3 Million
4:58pm on Friday 21st of August, 2026 AEST
Key Points
Secured EW-001 CAR-T therapy rights and commenced Australian manufacturing transfer
Reported promising clinical data with up to 50% response in advanced mesothelioma
Raised approximately A$5.3 million across three placements
Progressed partnering and patent protection for protein therapeutics AD-214 and WD-34
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE